AN2 Therapeutics to Participate at Upcoming Investor Conferences [Yahoo! Finance]
AN2 Therapeutics to Participate at Upcoming Investor Conferences
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of 13.4% in the US by 2034 | DelveInsight [Yahoo! Finance]